Is SYRE or TAK more undervalued in 2026?

CirclFi compares Spyre Therapeutics, Inc. (SYRE) and Takeda Pharmaceutical Company L (TAK) using 13 institutional-grade valuation models. SYRE has a Quality of Company score of 5.4/10 while TAK scores 7.4/10.

Which is a better buy — SYRE or TAK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SYRE and TAK valuations compare?

SYRE at $73.50 and TAK at $15.96 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SYRE vs TAK Valuation Comparison 2026 — Intrinsic Value Analysis

SYRE

Pharmaceutical Preparations

Spyre Therapeutics, Inc.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$73.50

Last close

Models

12/13

Active

TAK

Pharmaceutical Preparations

Takeda Pharmaceutical Company L

Quality

7.4

out of 10

Value Trap

LOW

Price

$15.96

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	SYRE Fair Value	SYRE Upside	TAK Fair Value	TAK Upside
Bayesian DCF	Intrinsic	$22.39	-69.5%	$36.57	+129.1%
Earnings Power Value	Intrinsic	$30.32	-56.5%	$21.77	+36.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SYRE vs TAK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SYRE vs TAK — Which Stock Is More Undervalued?

TAK scores higher with a 7.4/10 quality rating vs SYRE's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Spyre Therapeutics, Inc. (SYRE) and Takeda Pharmaceutical Company L (TAK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SYRE currently trades at $73.50 with a QOC of 5.4/10, while TAK trades at $15.96 with a QOC of 7.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).